Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7442 for post-exposure prophylaxis of COVID-19 (Phase III)
2020-004719-28Phase 3Unknown
- Sponsor
- AstraZeneca
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing AZD7442 single IM dose with Placebo single IM dose (2 arms). Primary endpoint: First RT-PCR-positive symptomatic COVID-19 case by Day 183. Status: unknown.
02
Drugs
tixagevimab + cilgavimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-004719-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004719-28.